Chinese vaccine spreading to the rich in Japan… Suga’s closest close-up was also beaten Jung Young-hyo’s Inside Japan

Sinoparm’s corona vaccine was brought in from November.. 18 people including representatives of large companies
Executives of economic organizations, Japanese Prime Minister Suga,’Brain’ are also on the list
Corona fear of rich Chinese and Japanese people aiming for’vaccine diplomacy’ combined
“Corona 19 infection cannot be allowed as a manager”

Corona 19 vaccine developed by China's Sinoparm (Source: Shinhwa)

Corona 19 vaccine developed by China’s Sinoparm (Source: Shinhwa)

It has been confirmed that some wealthy people, such as the presidents and families of large Japanese corporations and financial companies that anyone can know by name, secretly inoculate a new coronavirus infection (Corona 19) vaccine made in China that has not yet been approved by the Japanese government.

It is an analysis that this phenomenon is a combination of the Japanese wealthy’s anxiety over Corona 19, which is not halting the spread of Corona 19, and the Chinese government’s Noim Soo who is trying to use the Corona 19 vaccine as a diplomatic tool.

The Mainichi Newspaper reported on the 1st that at least 18 representatives of Japanese conglomerates and financial companies, family members, and acquaintances have inoculated since November of last year as the Corona 19 vaccine manufactured by China’s state-run pharmaceutical company Sinopharm (Chinese medicine group) was brought into Japan.

The number of Japanese people whose vaccination was confirmed is 15 men and 3 women. The newspaper reported that all of them are the chief executives and associates of companies representing Japan, such as financial companies, electronic conglomerates, and information technology (IT) companies. The executives in charge of the executives of the economic organization and the representatives of the companies who are considered the “brain” of Japanese Prime Minister Yoshihide Suga were also on the list.

A Chinese consultant close to an official of the Communist Party of China brings in a Chinese vaccine and lends a hospital to inoculate it on a day off. It is known that some wealthy people in Japan are vaccinated with a Chinese-made vaccine that has not been confirmed to be effective because of the fear of corona 19 infection.

The president of a financial company who inoculated with his wife twice on November 22nd and December 19th said, “If you are infected with Corona 19, your self-management is negligible, so it is impossible for a manager to be allowed.” According to the status, even though Corona 19 is in full swing, the dinner party cannot be avoided, so “I thought that it could be against the law,” he said.

A list of Chinese corona vaccine vaccinations and vaccination agreement obtained by the Mainichi Newspaper.

A list of Chinese corona vaccine vaccinations and vaccination agreement obtained by the Mainichi Newspaper.

The Japanese Medicines and Medical Devices Act recognizes the import of drugs, including vaccines, only when they are used for therapeutic purposes. It is analyzed that the conduct of a Chinese consultant who brought in a vaccine without permission for the purpose of selling or transferring it to another person is highly likely to be illegal.

There was also a case where’I thought that if I experienced the vaccine at least a little early, I could get a hint for starting a new business.’ (President of an IT company).

A Chinese consultant explained that in response to an interview by the Mainichi Newspaper, he had been asked by a Chinese Communist Party executive to “expand the base of Chinese vaccines in Japan.”

The corona vaccine developed by Pfizer and Modena et al. used a new technology called’mRNA vaccine’. When an mRNA vaccine instructing to make coronavirus protrusions is injected, cells make coronavirus protrusions by themselves according to the genetic information of the mRNA. Since mRNA vaccines have low stability, they should be stored at temperatures lower than normal vaccines (Pfizer is -70 degrees Celsius, Modena is -20 degrees Celsius).

On the other hand, the vaccine from China’s Sinofam was developed in an inactivated manner that prevents the bacteria from being activated. Compared to mRNA vaccines, it is cheaper and easier to store and transport.

Japan has already signed or agreed on a vaccine supply contract for 145 million people with Pfizer, Modena, and AstraZeneca. As domestic vaccines are also being developed, it is not easy for Chinese vaccines to open up a market in Japan.

Nevertheless, the reason China is operating Chinese vaccines to the wealthy in Japan is to be prepared in case of problems with the effectiveness and persistence of vaccines made in the US and Europe. The time will come when the Japanese government has no choice but to turn to Chinese vaccines.

A Chinese consultant said, “I gathered a list of Japanese influential people who had many opportunities to speak to the government in each field and contacted them individually,” he said. “In order to gain their trust, I sometimes asked an executive of a Japanese pharmaceutical company to attend.”

In fact, on November 7th, after a group of male entrepreneurs inoculated a large company with their own hands, the confidence in the Chinese vaccine increased, and the number of applicants for vaccination increased. The consultant said, “From this year, we plan to contact members of the Liberal Democratic Party, who are influential in the Ministry of Health, Labor and Welfare.”

After the spread of Corona 19, China is focusing on developing vaccines that will stand shoulder to shoulder with the United States and Europe. Chinese President Xi Jinping designated the Chinese-made Corona 19 vaccine as an’international public good’ and declared that “we will provide priority to developing countries.” It is pointed out that China is trying to use the corona vaccine as a means of diplomacy. The analysis of this newspaper is that increasing the number of vaccination cases in Japan is a preliminary step in’vaccine diplomacy’.

Tokyo = correspondent Jeong Young-hyo [email protected]

Source